Representativeness of Phase III Trial for Osimertinib in Pretreated Advanced EGFR-Mutated Non-small-cell Lung Cancer Patients and Treatment Outcomes in Clinical Practice
- Lishi Lin
- , Egbert F. Smit
- , Adrianus J. de Langen
- , Dorieke E.M. van Balen
- , Jos H. Beijnen
- , Alwin D.R. Huitema
Onderzoeksoutput: Bijdrage aan tijdschrift › Artikel › peer review
3
Citaten
(Scopus)